These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38547657)

  • 1. Identification of CREB5 as a prognostic and immunotherapeutic biomarker in glioma through multi-omics pan-cancer analysis.
    Wu Z; Wang X; Wu H; Du S; Wang Z; Xie S; Zhang R; Chen G; Chen H
    Comput Biol Med; 2024 May; 173():108307. PubMed ID: 38547657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
    Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
    Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
    Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
    Front Immunol; 2022; 13():849592. PubMed ID: 35444654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CREB5 promotes invasiveness and metastasis in colorectal cancer by directly activating MET.
    Wang S; Qiu J; Liu L; Su C; Qi L; Huang C; Chen X; Zhang Y; Ye Y; Ding Y; Liang L; Liao W
    J Exp Clin Cancer Res; 2020 Aug; 39(1):168. PubMed ID: 32843066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A potential immunotherapeutic and prognostic biomarker for multiple tumors including glioma: SHOX2.
    Wu X; Chen H; You C; Peng Z
    Hereditas; 2023 May; 160(1):21. PubMed ID: 37170390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: A multi-omics analysis with experimental verification.
    Peng Z; Wang J; Tong S; Wu Y; Yi D; Xiang W
    Front Immunol; 2023; 14():1128151. PubMed ID: 37006287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers.
    Tai P; Wang Z; Chen X; Chen A; Gong L; Cheng Y; Cao K
    Cancer Med; 2023 May; 12(10):11941-11959. PubMed ID: 36205192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. microRNA-206 prevents hepatocellular carcinoma growth and metastasis via down-regulating CREB5 and inhibiting the PI3K/AKT signaling pathway.
    Chi Y; Gong Z; Xin H; Wang Z; Liu Z
    Cell Cycle; 2022 Dec; 21(24):2651-2663. PubMed ID: 36003063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA SNHG5 affects cell proliferation, metastasis and migration of colorectal cancer through regulating miR-132-3p/CREB5.
    Zhang M; Li Y; Wang H; Yu W; Lin S; Guo J
    Cancer Biol Ther; 2019; 20(4):524-536. PubMed ID: 30395767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid-liquid phase separation-related gene in gliomas: FABP5 is a potential prognostic marker.
    Tang Q; Mao X; Chen Z; Ma C; Tu Y; Zhu Q; Lu J; Wang Z; Zhang Q; Wu W
    J Gene Med; 2023 Oct; 25(10):e3517. PubMed ID: 37114595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-Cancer Analysis Identifies CHD5 as a Potential Biomarker for Glioma.
    Xu L; Shao F; Luo T; Li Q; Tan D; Tan Y
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGIF2 is a potential biomarker for diagnosis and prognosis of glioma.
    Zhang W; Zhang L; Dong H; Peng H
    Front Immunol; 2024; 15():1356833. PubMed ID: 38629068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative multi-omics analyses unravel the immunological implication and prognostic significance of CXCL12 in breast cancer.
    Gao ZJ; Fang Z; Yuan JP; Sun SR; Li B
    Front Immunol; 2023; 14():1188351. PubMed ID: 37564657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancancer landscape analysis of the thymosin family identified TMSB10 as a potential prognostic biomarker and immunotherapy target in glioma.
    Xiong Y; Qi Y; Pan Z; Wang S; Li B; Feng B; Xue H; Zhao R; Li G
    Cancer Cell Int; 2022 Sep; 22(1):294. PubMed ID: 36163046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiomics blueprint of PANoptosis in deciphering immune characteristics and prognosis stratification of glioma patients.
    Chen M; Huang M; Chen X; Lin X; Chen X
    J Gene Med; 2024 Jan; 26(1):e3621. PubMed ID: 37997255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-204/CREB5 axis regulates vasculogenic mimicry in breast cancer cells.
    Contreras-Sanzón E; Palma-Flores C; Flores-Pérez A; M Salinas-Vera Y; B Silva-Cázares M; A Marchat L; G Avila-Bonilla R; N Hernández de la Cruz O; E Álvarez-Sánchez M; Pérez-Plasencia C; D Campos-Parra A; López-Camarillo C
    Cancer Biomark; 2022; 35(1):47-56. PubMed ID: 35662106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-omics analysis reveals the involvement of origin recognition complex subunit 6 in tumor immune regulation and malignant progression.
    Zhu J; Chen Q; Zeng L; Gao H; Wu T; He Y; Xu J; Pang J; Peng J; Deng Y; Han Y; Yi W
    Front Immunol; 2023; 14():1236806. PubMed ID: 37901236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Prognostic Analysis of Immune Implication Value and Oxidative Stress Significance of NECAP2 in Low-Grade Glioma.
    Lu Z; Chen Y; Chen S; Zhu X; Wang C; Wang Z; Yao Q
    Oxid Med Cell Longev; 2022; 2022():1494520. PubMed ID: 36531205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy.
    Ye F; Wang L; Li Y; Dong C; Zhou L; Xu J
    Front Immunol; 2023; 14():1338244. PubMed ID: 38250074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.